Letter by Zhou et al Regarding Article, "Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease"

Circulation. 2023 Apr 18;147(16):1256-1257. doi: 10.1161/CIRCULATIONAHA.122.062742. Epub 2023 Apr 17.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Anticholesteremic Agents* / adverse effects
  • Atherosclerosis* / drug therapy
  • Cardiovascular Diseases* / drug therapy
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors*

Substances

  • evolocumab
  • Antibodies, Monoclonal, Humanized
  • Anticholesteremic Agents
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors